期刊文献+

不同免疫抑制诱导治疗对肝移植受者CD4^+ CD25^(+high)细胞的影响 被引量:1

Impact of induction with different immunosuppressants on CD4^+ CD25^+ regulatory T cells in liver transplanted recipients
下载PDF
导出
摘要 目的CD4+ CD25+Treg细胞介导的免疫调节对诱导和维持移植物免疫耐受有非常重要的作用,本研究探讨抗胸腺淋巴细胞球蛋白(ATG)和噻呢哌这两种不同作用途径的免疫抑制诱导药物对CD4+ CD25+high/CD4+T细胞及其表面标志性因子CTLA-4、Foxp3的影响,为临床合理选择应用免疫诱导药物提供依据。方法选择15例在我院行同种异体肝移植患者,随机分为ATG组(8例)和噻呢哌组(7例),两组除免疫抑制诱导药物不同外,均接受相同治疗。分别于术前、术后3周、6周、8周取血,应用流式细胞仪检测CD4+ CD25+high/CD4+ T细胞的数量及其表面因子CTLA-4和Foxp3表达状况,比较不同诱导药物对其影响。结果这两种免疫抑制诱导药物对CD4+ CD25+Treg细胞短期内有一定影响,但可逐渐恢复,两者比较,使用ATG后各指标恢复较噻呢哌快,尤其是Foxp3更加明显。结论作为诱导治疗药物,ATG更有利于CD4+ CD25+T细胞功能恢复,从而有助于更好形成移植免疫耐受。 Objective There is now a great degree of consensus that the CD4^+ CD25^+ regulatory T cells( CD4^+ CD25^+ Treg ) play an important role in beth the induction and the maintenance of the transplant tolerance , so it is necessary to have intensive investigations on them, including the change of Treg cells and the expression of molecular markers , CTLA-4 and Foxp3. It is well known that the used immunosuppressive drugs currently may affect the number and the function of the CD4^+ CD25^+ Trig and as a result , hinder the establishment of transplant tolerance. This study focus on the impact of two inductive immunosuppressive drugs, anti-thymcyte globulin(ATG) and Zenapax on CD4^+ CD2.5^+ Treg in liver transplant recipients. Methods 15 liver transplant recipients aged 20 - 50 were chosen and divided into ATG group( n = 8) and Zenapax group ( n = 7). ATG or Zenapax were given as the inductive drugs. The maintenance drugs of the two groups are the same. FACScan Flow cytometry were used to test the CD4^+ CD25^+high/CD4^+ ,CTLA-4 and Foxp3 of the blood sample at four time ends : Pre-use, 3th week, 6th week and 8th week after transplantation. Results Though beth two inductive drugs can decrease the number of CD4^+ CD25^+ Treg and the expression of surface molecules, the Tregs can increase gradually. The ATG group recovered faster than the zenapax group. The difference was significant. Conclusion As the inductive drug, ATG may be better for the recovery of the CD4^+ CD25^+ Treg and as a result, better for the induction of transplant tolerance.
出处 《肝脏》 2007年第1期22-25,共4页 Chinese Hepatology
关键词 免疫调节细胞 CD4^+CD25^+ 免疫抑制剂 肝移植 T regulatory cells CD4^+ CD25^+ Immunosupressive drug liver transplantation
  • 相关文献

参考文献19

  • 1Hara M,Kingsley C,Niimi M,et al.IL-10 in required for regulatory T cells to mediate tolerance to alloantigens in vivo.J Immunol,2001,166:3789.
  • 2Kingsley CI,Karim M,Bushell AR,et al.CD4^+CD25^+ regulatory T cells prevent graft rejection:CTLA-4-and IL-10-dependent immunoregulation of alloresponses.J Immunol,2002,168:1080-1086.
  • 3Taams LS,Smith MH,Rustin M,et al.Human anergie/suppressive CD4^+CD25^+ T cells:a highly differentiated and apoptosis-prone population.Eur J Immunol,2001,31:1122-1131.
  • 4Sakaguchi S,Sakaguchi N,Asano M,et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor lpha-ehains (CD25).Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.J Immunol,1995,155:1151-1164.
  • 5Hoffmann P,Ermann J,Edinger M,et al.Donor-type CD4 + CD25 + regulatory T cells suppress lethal acute graft-remus-host disease after allogeneic bone marrow transplantation.J Exp Med,2002,196:389.
  • 6Sanchez-Fueyo A,Weber M,Domenig C,et al.Tracking immunoregulatory mechanisms during allograft tolerance.J Immunol,2002,169:2274.
  • 7Clare BA,Julia AB,Gordon JF,et aL.CD4^+CD25^high regulatory cells in human peripheral blood.J Immunology,2001,167:1245-1253.
  • 8Hori S,Nomura T,Sakaguchi S.Control of regulatory T cell development by the transcription factor Foxp3.Science,2003,299:1057.
  • 9Dieckmann D,Plottner H,Berchtold S,et al.Ex vivo isolation and characterization of CD4(+)CD25(+)T cells with regulatory properties from human blood.J Exp Med,2001,193:1303.
  • 10Eggena MP,Walker LS,Nagabhushanam V,et al.Cooperative roles of CTLA-4 and regulatory T cells in tolerance to an islet cell antigen.J Exp Med.2004,199,1725.

同被引文献18

  • 1蒋启发,谢荣华.CD4^+ CD25^+ T细胞研究新进展[J].实用预防医学,2007,14(1):249-252. 被引量:6
  • 2郑永先,侯桂华,宋静,张超,梁婷.雷帕霉素对同种移植耐受模型CD4^+CD25^+ T细胞活性的影响[J].细胞与分子免疫学杂志,2007,23(4):327-330. 被引量:3
  • 3Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2receptor-chains(CD25). J Immunol,1995,155:1151-1164.
  • 4Maggi E, Cosmi L, Liotta F, et al. Thymic regulatory T cells. Autoimmun Rev,2005,4:579-586.
  • 5Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of a new forkhead/winged -helix protein,scurfin,resuhs in the fatal lymphoproliferative disorder of the scurfy morse. Nat Genet,2001,27:68-73.
  • 6Koonpaew S, Shen S, Flowers L, et al. LAT-mediated signaling in CD4+CD25+ regulatory T cell development. J Exp Med,2006,203: 119-129.
  • 7Read S, Greenwald R, Lzcue A, et al. Blockade of CTLA-4 on CD4+CD25+regulatory T cells abrogates their function in vivo. J Immunol,2006,177:4376-4383.
  • 8Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4^+ CD25^+ Foxp3^+ regulatory T cells. Blood, 2005,105: 4743 - 4748.
  • 9Bacehetta R, Passefini L, Gambineri E, et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutafions.J Clin Invest,2006,116:1473-1475.
  • 10Miyara M, Sakaguchi S. Natural regulatory T cells:mechanisms of suppression.Trends Mol Med,2007,13:108-116.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部